Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common

Stephen Booth, MA,MBBChir,MRCP,FRCPath, Hannah Plaschkes, Amy A Kirkwood, Adam Gibb, MBBS, Patrick Horgan, Joanna M Oladipo, Joseph Andrew Browning, DPhil,BMBCh, Usman Khan, John Willan, Julia Wolf, Arief Gunawan, MBBS, BSc, MRCP, Paul A Fields, MD PhD, Kim Linton, MBChB PhD, Claire Higham, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Jaimal Kothari, Catherine Hildyard, Toby A. Eyre

Blood (2019) 134 (Supplement_1): 1615.

https://doi.org/10.1182/blood-2019-127374

Published: 2019

Journal Articles

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Graham P. Collins, MB BS DPhil, Steven M. Horwitz, MD, Andrew Davies, Anand Karnad, MD, Felipe Samaniego, MD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Joseph Boni, PhD, Hans Cruz, Jay Feingold, MD PhD, Shui He, PhD, Jens Wuerthner, Mehdi Hamadani, MD

Blood (2018) 132 (Supplement 1): 1658.

https://doi.org/10.1182/blood-2018-99-115986

Published: 2018

Journal Articles

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Steven M. Horwitz, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Jay Feingold, MD PhD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Anand Karnad, MD, Alison J. Moskowitz, MD, Catherine Hildyard, MRCP, BA, Shui He, PhD, Joseph Boni, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 1510.

https://doi.org/10.1182/blood.V130.Suppl_1.1510.1510

Published: 2017

Journal Articles

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

Betty Gration, MBBS, Ana Duran, MD, Naheed Mir, BSc, FRCP, FRCPath, Lisa Yuen, MPharm, PgDip, IP, Marcus Warner, MPharm, PG Dip GPP, Karen Stanley, RGN, MSc Advanced Practice, Jessica Brady, MBBCh, FRCR, George Mikhaeel, MB BCh, MSc, FRCR, Paul A Fields, MD PhD, David Wrench, MA, MBBChir, FRCPath, PhD

Blood (2017) 130 (Supplement 1): 4133.

https://doi.org/10.1182/blood.V130.Suppl_1.4133.4133

Published: 2017

Journal Articles

The Thalidomide Analogue (Actimid) Induces T-Cell Activation at Day 28 in Patients with Relapsed Refractory Myeloma but Does Not Correlate with Improved Outcome.

Gulrukh Ahsan, MSc, Mathew Streetly, MD, Paul A. Fields, MD, PhD, Auther R. Bradwell, PhD, Steve A. Schey, MD, Majid Kazmi, MD

Blood (2005) 106 (11): 3473.

https://doi.org/10.1182/blood.V106.11.3473.3473

Published: 2005

Journal Articles

B Cell Post Transplant Lymphoproliferative Disorder Complicating Solid Organ Transplantation (B-PTLD): A Single Centre Review Reporting 1) Results with Chemo-Immunotherapy (CHOP/R) and 2) the Predictive Ability of FDG-PET Scanning To Correlate with Long Term Overall Survival.

Sameer Tulpule, MD, George Mikhaeel, MD, Majid Kazmi, MD, Tom Nunan, MD, John Van Der Walt, MD, David Goldsmith, MD, Paul A. Fields, MD, PhD

Blood (2005) 106 (11): 1500.

https://doi.org/10.1182/blood.V106.11.1500.1500

Published: 2005

NARROW

Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

The Thalidomide Analogue (Actimid) Induces T-Cell Activation at Day 28 in Patients with Relapsed Refractory Myeloma but Does Not Correlate with Improved Outcome.

B Cell Post Transplant Lymphoproliferative Disorder Complicating Solid Organ Transplantation (B-PTLD): A Single Centre Review Reporting 1) Results with Chemo-Immunotherapy (CHOP/R) and 2) the Predictive Ability of FDG-PET Scanning To Correlate with Long Term Overall Survival.

Email alerts

ASH Publications

American Society of Hematology

Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy

The Thalidomide Analogue (Actimid) Induces T-Cell Activation at Day 28 in Patients with Relapsed Refractory Myeloma but Does Not Correlate with Improved Outcome.

B Cell Post Transplant Lymphoproliferative Disorder Complicating Solid Organ Transplantation (B-PTLD): A Single Centre Review Reporting 1) Results with Chemo-Immunotherapy (CHOP/R) and 2) the Predictive Ability of FDG-PET Scanning To Correlate with Long Term Overall Survival.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only